45 related articles for article (PubMed ID: 34861455)
1. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J; Dima D; Li H; Hansen D; Sidana S; Shune L; Anwer F; Sborov D; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Peres L; Hovanky V; Simmons G; Williams L; Raza S; Afrough A; Anderson L; Fererri C; Hashmi H; Davis J; McGuirk J; Goldsmith S; Borogovac A; Lin Y; Midha S; Nadeem O; Locke FL; Baz R; Hamilton B; Alsina M; Sauter C; Patel K; Kaur G
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38834151
[TBL] [Abstract][Full Text] [Related]
2. Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.
Cheng H; Ji S; Wang J; Hua T; Chen Z; Liu J; Shao L; Wang X; Chen W; Sang W; Qi K; Li Z; Sun C; Shi M; Qiao J; Wu Q; Zeng L; Fei X; Huang H; Gu W; Xu K; Zheng J; Cao J
Clin Exp Med; 2023 Dec; 23(8):5241-5254. PubMed ID: 37907623
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H
Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316
[TBL] [Abstract][Full Text] [Related]
4. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D; Abdallah AO; Davis JA; Awada H; Goel U; Rashid A; DeJarnette S; Anwer F; Shune L; Raza S; Mahmoudjafari Z; Williams L; Faiman B; McGuirk JP; Sauter CS; Ahmed N; Khouri J; Hashmi H
Blood Cancer J; 2024 May; 14(1):90. PubMed ID: 38821914
[TBL] [Abstract][Full Text] [Related]
5. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
Akhtar OS; Modi K; Kim J; Skelson L; Smith E; Al-Jumayli MA; Extermann M; De Avila G; Parker N; Castaneda Puglianini O; Grajales Cruz A; Baz R; Blue B; Shain K; Alsina M; Liu H; Nishihori T; Jain MD; Locke FL; Hansen DK; Freeman CL
Transplant Cell Ther; 2024 Mar; 30(3):283.e1-283.e10. PubMed ID: 38123069
[TBL] [Abstract][Full Text] [Related]
6. Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma.
Mejia Saldarriaga M; Pan D; Unkenholz C; Mouhieddine TH; Velez-Hernandez JE; Engles K; Fein JA; Monge J; Rosenbaum CA; Pearse R; Jayabalan DS; Gordillo CA; Chan HT; Yamshon S; Thibaud S; Mapara MY; Inghirami GG; Lentzsch S; Reshef R; Rossi A; Parekh S; Jagannath S; Richard S; Niesvizky R; Bustoros M
Blood Adv; 2024 May; ():. PubMed ID: 38776397
[TBL] [Abstract][Full Text] [Related]
7. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B; Chu L; Ortiz-Maldonado V; Warmuth L; Barba P; Doglio M; Henderson D; Hudecek M; Kremer A; Markman J; Nauerth M; Negre H; Sanges C; Staber PB; Tanzi R; Delgado J; Busch DH; Kuball J; Luu M; Jäger U
Front Immunol; 2023; 14():1303935. PubMed ID: 38187393
[TBL] [Abstract][Full Text] [Related]
8. Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer.
Horimoto Y; Jimbo H; Ishizuka Y; Nogami N; Kutomi G; Watanabe J
BMJ Support Palliat Care; 2024 Jun; ():. PubMed ID: 38834236
[TBL] [Abstract][Full Text] [Related]
9. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.
Bal S; Costa LJ
Br J Haematol; 2024 Feb; 204(2):449-454. PubMed ID: 38036424
[TBL] [Abstract][Full Text] [Related]
10. Correction: Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS.
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38114234
[No Abstract] [Full Text] [Related]
11. Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission.
Xu K
Blood Sci; 2024 Jan; 6(1):e00177. PubMed ID: 38213826
[No Abstract] [Full Text] [Related]
12. Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy.
Rejeski K; Cordas Dos Santos DM; Parker NH; Bücklein VL; Winkelmann M; Jhaveri KS; Liu L; Trinkner P; Günther S; Karschnia P; Blumenberg V; Schmidt C; Kunz WG; von Bergwelt-Baildon M; Jain MD; Theurich S; Subklewe M
Cancer Immunol Res; 2023 Jun; 11(6):707-719. PubMed ID: 37040425
[TBL] [Abstract][Full Text] [Related]
13. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
14. Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
Liu Y; Chen W; Yu M; Li H; Cheng H; Cao J; Yan Z; Shi M; Zhu F; Sun H; Sang W; Li D; Wu Q; Chen C; Zheng J; Xu K; Li Z
Transplant Cell Ther; 2022 Feb; 28(2):118.e1-118.e5. PubMed ID: 34861455
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.
Lu Y; Zhu H; Liu Y; Wang Y; Sun Y; Cheng H; Yan Z; Cao J; Sang W; Zhu F; Li D; Sun H; Zheng J; Xu K; Li Z
Front Immunol; 2023; 14():1155216. PubMed ID: 37205117
[TBL] [Abstract][Full Text] [Related]
16. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y; Jie X; Nian L; Wang Y; Wang C; Ma J; Jiang J; Wu Q; Qiao J; Chen W; Cao J; Yan Z; Shi M; Cheng H; Zhu F; Sang W; Li D; Chen C; Xu K; Li Z
Front Immunol; 2023; 14():1169071. PubMed ID: 37153543
[TBL] [Abstract][Full Text] [Related]
17. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
18. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
19. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche JC
Semin Hematol; 2023 Jan; 60(1):52-58. PubMed ID: 37080711
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]